Why Moderna Stock Rose Today
Shares of Moderna (NASDAQ: MRNA) climbed 3.6% on Thursday after the drugmaker announced the completion of enrollment for its COVID-19 vaccine study. Moderna has enrolled 30,000 people for the phase 3 trial for its coronavirus vaccine candidate, mRNA-1273. The biotech noted that 42% of the participants are from groups deemed to be at high risk of severe COVID-19 disease, including more than 7,000 Americans over the age of 65 and 5,000 people who are younger but have chronic diseases, such as severe obesity and diabetes.
